Miniature implantable illuminator for photodynamic therapy

Details Miniature implantable illuminator for photodynamic therapy Miniature implantable illuminator for photodynamic therapy

2002-02-06

2003-09-16

Walberg, Teresa (Department: 3742)

Surgery: light, thermal, and electrical application

Light, thermal, and electrical application

Electrical therapeutic systems

C607S001000, C607S088000, C607S030000, C607S033000, C607S061000, C600S001000, C600S003000

Reexamination Certificate

active

06622049

ABSTRACT:

FIELD AND BACKGROUND OF THE INVENTION
The present invention is generally directed to a miniature light source for administering photodynamic therapy (PDT), a system incorporating same, and a method for providing such treatment, and more specifically, pertains to an minimal invasively implantable miniature light source which is operably coupled to a power supply that is either acoustically energized or acoustically activated to operate, and to a method for using such a miniature light source to administer PDT.
A tumor comprising abnormal cells is known to selectively absorb certain dyes perfused into the site to a much greater extent than surrounding tissue. For example, compared to normal cells, intracranial gliomas absorb up to a 28 times as much dye. Once pre-sensitized by dye tagging in this manner, the cancerous or abnormal cells can be destroyed by irradiation with light of an appropriate wavelength, several discrete wavelengths or waveband corresponding to an absorbing wavelength, several discrete wavelengths or waveband of the dye, with minimal damage to normal tissue. This procedure, which is known as photodynamic therapy (PDT), has been clinically used to treat metastatic breast cancer, bladder cancer, lung carcinomas, esophageal cancer, basal cell carcinoma, malignant melanoma, ocular tumors, head and neck cancers, and other types of malignant tumors, and for destroying pathogens. Because PDT may be selective in destroying abnormal cells that have absorbed more of the dye, it can successfully be used to kill malignant tissue or organisms with less effect on surrounding benign tissue in the brain and other critical areas.
Typically, invasive applications of PDT have been used during surgical procedures employed to gain access to a treatment site inside the body of the patient. Relatively high intensity light sources have traditionally been used to reduce the duration of the treatment, and thus the time required for the surgery used to expose the treatment site, and because the majority of the prior art teaches that very high intensity light will more likely kill all of the malignant cells. Optical fibers in a hand-held probe are often used to deliver the intense light to the surgically exposed treatment site from a remote light source to reduce damage to surrounding tissue from the heat developed by the light source. High power lasers or solid-state laser diode (LD) arrays in a remote light source coupled to the optical fibers are normally used. A typical prior art light source for PDT would provide from about 0.10 watts to more than 1.0 watts of optical power to achieve the high intensity, short duration exposures that are preferred. Because of the relatively high light intensity and power required to achieve it, apparatus to provide PDT is often physically too large and too heavy to be readily moved about with the patient.
The theoretical basis behind PDT is that the light energy absorbed by dye molecules in the malignant or pathogen cells is transferred to dissolved oxygen to produce a reactive species called “singlet oxygen.” This highly reactive form of oxygen kills cancer cells, damages tumor vasculature, and can destroy viruses and bacteria. Since the concentration of dissolved oxygen in cells is comparatively low, it is possible that after all available oxygen is activated and/or reacted with the cell materials, any additional increase in light intensity will have a negligible incremental effect on the tumor or in killing malignant cells. The limiting factor on the rate of malignant cell death in PDT may well be the rate at which additional oxygen diffuses into the treatment site from surrounding tissue and through replenishment via the vascular system. Contrary to the teachings of most of the prior art, the effectiveness of each photon of light impacting the treatment area may be highest at very low light intensities, provided over extended treatment times, and the optical efficiency may in fact decrease with increasing exposure level.
Several researchers, including Haas et al, “Photodynamic Effects of Dyes on Bacteria” Published in Mutation Researchh, 1979, vol. 60, pp. 1-11, have shown that the level of cytotoxicity in PDT appears to be proportional to the product of the integrated light exposure and the photoreactive agent's concentration, rather than to the instantaneous light intensity. In other words, the degree of PDT response is dominated by the total amount of light absorbed by the photoreactive agent over the treatment period. It can therefore be argued that if: (i) the photoreactive agent's concentration in the target tissue is maintained at a therapeutic level; and (ii) apparatus for delivering light of the proper wavelength, several discrete wavelengths or waveband to a treatment site over an extended period is available, then the benefits of PDT can be realized with a less aggressive and potentially less costly treatment carried out over a period ranging from days to weeks. Longer treatment periods at lower dosage rates may have other benefits as well, since high dosage rates continued over extended periods can result in adverse normal tissue response.
Maintenance of therapeutic photoreactive agent levels at a treatment site in the body is not difficult. It is well known that many PDT photoreactive agents have a long half-life in the human body. In some cases, however, it is necessary for a patient to avoid direct sunlight for up to 30 days to avoid sunburn or phototoxic side effects of the photoreactive agents that are infused into the body.
Teachings in the prior art have shown that it is possible, in certain cases, to obtain improved therapeutic results in PDT at a low light level. As reported by J. A. Parrish in “Photobiologic Consideration in Photoradiation Therapy,” pp. 91-108, Porphyrin Photosensitization, Plenum Press, (1983), preliminary laboratory studies with hematoporphyrin and visible light suggest that the reciprocity effect does not always hold, and that low light intensity may be more effective in PDT, in an absolute sense. In these experiments, subcutaneous tumors in the flanks of newborn rats were treated with the same external dose of 620 nm radiation at intensities of 7.5, 28, and 75 mW/cm
2
. At the same total light dosage, Parrish found that greater tumor necrosis occurred at the lowest light intensity used.
In addition, several researchers have shown that combinations of certain photoreactive agents and low light levels exhibit very potent cytotoxicity. Some studies have shown that more than 99% of gram-positive
Staphylococcus aureus
and
Streptococcus faecalis
bacterial cultures can be killed with the application of 5
2
mW/cm of broad band light from a tungsten bulb for 30 minutes, if the cultures are initially dosed with 1-10 micrograms/ml of deuteroporphyrin. Continued application of light for ten to eleven hours results in a sterile condition in the culture, i.e., no bacteria remain alive.
Labrousse and Satre “Photodynamic Killing of Dictyostelium discoideum Amoebae Mediated by 4′,5′-Diiodoflurescin Isothiocyanate Dextran. A strategy for the isolation of Thermoconditional Endocytosis Mutants”, published in Photochemistry and Photobiology, 1993, vol. 67, No. 3, pp. 531-537, have demonstrated a similar photodynamic extermination of amoebae when dosed with low concentrations of 4′5′-Diiodofluorescein isothiocyanate dextran and irradiated for about 30 minutes with broad band light of 8-10 mW/cm
2
from a tungsten lamp. Both of these experimental results are particularly significant because the fraction of a tungsten lamp's output energy that can be absorbed by either photoreactive agent is small, since each agent has a narrow absorbance waveband.
For all PDT light sources, the vast majority of the optical power delivered to tissue eventually degrades to heat. From a therapy perspective, it is likely that this heat load will augment the treatment due to improved chemical reaction rates at higher tissue temperatures. It is also true that cells kept above approximately 43° C. are no

Affiliated with

Also associated with

Rating

Miniature implantable illuminator for photodynamic therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Miniature implantable illuminator for photodynamic therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Miniature implantable illuminator for photodynamic therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3031017